Mar 2, 2026 04:05PM
Dec 22, 2025 07:06AM
Dec 1, 2025 08:02AM
Dec 1, 2025 08:00AM
Nov 5, 2025 04:05PM
Aug 21, 2025 08:00AM
Aug 21, 2025 08:00AM Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia
Aug 14, 2025 04:05PM
Jun 30, 2025 08:00AM
May 8, 2025 04:05PM
Mar 27, 2025 04:05PM
Jan 29, 2025 04:06PM
Jan 29, 2025 04:05PM
Jan 22, 2025 08:00AM Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium
Jan 10, 2025 08:06AM
Jan 10, 2025 08:00AM
Jan 2, 2025 12:51PM
Nov 7, 2024 04:05PM
Oct 28, 2024 10:42AM
Oct 28, 2024 07:00AM
Oct 28, 2024 07:00AM Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)
Oct 24, 2024 06:21PM
Sep 10, 2024 04:05PM
Sep 10, 2024 04:05PM
Aug 7, 2024 04:05PM
Jul 2, 2024 04:05PM
Jul 2, 2024 04:05PM
May 9, 2024 04:05PM Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights
May 7, 2024 04:06PM
May 7, 2024 04:05PM
Mar 19, 2024 04:05PM
Feb 1, 2024 05:30PM
Feb 1, 2024 05:30PM
Dec 22, 2023 09:00AM
Nov 7, 2023 04:05PM Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights
Aug 10, 2023 04:05PM
Aug 1, 2023 08:02AM
Aug 1, 2023 08:00AM
May 4, 2023 04:05PM
Mar 22, 2023 04:05PM
Mar 1, 2023 07:02AM
Mar 1, 2023 07:00AM Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia
Nov 3, 2022 04:05PM
Nov 2, 2022 04:09PM
Nov 2, 2022 04:05PM
Sep 5, 2022 08:15AM
Aug 4, 2022 04:05PM
May 5, 2022 04:05PM
Mar 3, 2022 04:05PM Tyra Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights
Nov 3, 2021 04:05PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All